A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers-Reference-Cited by-同舟云学术

A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers

Published:2018-07-20 Issue:9 Volume:16 Page:1722-1731
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Cardinal M.¹,Kantaridis C.²,Zhu T.³,Sun P.³,Pittman D. D.¹,Murphy J. E.¹,Arkin S.¹

Affiliation:

1. Rare Disease Research Unit; Pfizer Inc.; Cambridge MA USA

2. Pfizer Clinical Research Unit; Brussels Belgium

3. Early Clinical Development; Pfizer Inc.; Cambridge MA USA

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.14207/fullpdf

Reference18 articles.

1. Novel approaches to hemophilia therapy: successes and challenges;Arruda;Blood,2017

2. Tissue factor pathway inhibitor: structure-function;Broze;Front Biosci,2014

3. Biology of tissue factor pathway inhibitor;Wood;Blood,2014

4. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ;Maroney;J Thromb Haemost,2013

5. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition;Warn-Cramer;Thromb Haemost,1988

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MEK1/2‐ and ERK1/2‐Mediated Lung Endothelial Injury and Altered Hemostasis Promote Diffuse Alveolar Hemorrhage in Murine Lupus;Arthritis & Rheumatology;2024-07-30

2. Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives;Biomolecules;2024-07-15

3. Joint health and pain in the changing hemophilia treatment landscape;Expert Review of Hematology;2024-07-15

4. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders;Research and Practice in Thrombosis and Haemostasis;2024-05

5. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27